与2型糖尿病、空腹血糖和HbA1c水平相关的DNA甲基化标志物:系统综述及Lifelines研究病例对照样本中的重复验证
该系统综述检索PubMed和EMBASE中的全表观基因组关联研究(EWAS),从15项EWAS中选取100个独特CpG位点,在Lifelines研究的100例2型糖尿病患者和100例对照者的全血甲基化数据中进行重复验证。52个血液来源CpG中15个与2型糖尿病名义显著相关,5个(ABCG1、LOXL2、TXNIP、SLC1A5、SREBF1)经严格多重检验校正后仍显著,方向与原始EWAS一致;组织特异性EWAS的CpG未在全血中重复,HbA1c相关CpG未重复,空腹血糖有2个CpG名义重复。作者认为这些CpG有望作为疾病生物标志物,但需更多前瞻性研究支持其稳健性。
要点
- 5个CpG(ABCG1、LOXL2、TXNIP、SLC1A5、SREBF1)与2型糖尿病关联经严格多重检验校正后仍显著。
- 组织特异性EWAS的CpG未能在全血甲基化数据中重复。
- HbA1c相关CpG未在健康对照中重复,空腹血糖有2个CpG名义重复。
核心结论
- EWAS文献中报道的若干与2型糖尿病相关的差异甲基化CpG在全血中得到重复验证,有望作为疾病生物标志物用于临床。
- 需要更多前瞻性研究来支持这些发现的稳健性。
研究设计与样本
- 系统综述:在PubMed和EMBASE中检索EWAS,审查DNA甲基化与2型糖尿病和/或血糖性状的关联。
- 重复验证:从15项EWAS中选取100个独特CpG(来自外周血、胰腺、脂肪组织和肝脏),采用研究特定的Bonferroni校正显著性阈值。
- 重复验证样本:Lifelines研究中100例2型糖尿病患者和100例对照者的全血甲基化数据(Illumina 450K芯片)。
- 统计方法:多变量线性模型检验特定CpG与2型糖尿病及血糖性状的关联。
主要发现
- 从血液中识别并选入重复验证的52个CpG中,15个与2型糖尿病呈名义显著关联(p < 0.05)。
- 5个CpG(位于ABCG1、LOXL2、TXNIP、SLC1A5和SREBF1)经严格多重检验校正后仍显著(甲基化变化从-3%至3.6%,p < 0.0009)。
- 所有关联的方向与原始EWAS结果一致。
- 来自组织特异性EWAS的所选CpG均未在全血甲基化数据中重复。
- 在健康对照个体中未能重复任何与HbA1c水平相关的CpG;空腹血糖有2个CpG(位于ABCG1和CCDC57)在名义显著性水平上重复(p < 0.05)。
局限性
- 需要更多前瞻性研究来支持这些发现的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Epigenetic mechanisms may play an important role in the aetiology of type 2 diabetes. Recent epigenome-wide association studies (EWASs) identified several DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA1c levels. Here we present a systematic review of these studies and attempt to replicate the CpG sites (CpGs) with the most significant associations from these EWASs in a case-control sample of the Lifelines study. METHODS: We performed a systematic literature search in PubMed and EMBASE for EWASs to test the association between DNA methylation and type 2 diabetes and/or glycaemic traits and reviewed the search results. For replication purposes we selected 100 unique CpGs identified in peripheral blood, pancreas, adipose tissue and liver from 15 EWASs, using study-specific Bonferroni-corrected significance thresholds. Methylation data (Illumina 450K array) in whole blood from 100 type 2 diabetic individuals and 100 control individuals from the Lifelines study were available. Multivariate linear models were used to examine the associations of the specific CpGs with type 2 diabetes and glycaemic traits. RESULTS: From the 52 CpGs identified in blood and selected for replication, 15 CpGs showed nominally significant associations with type 2 diabetes in the Lifelines sample (p < 0.05). The results for five CpGs (in ABCG1, LOXL2, TXNIP, SLC1A5 and SREBF1) remained significant after a stringent multiple-testing correction (changes in methylation from -3% up to 3.6%, p < 0.0009). All associations were directionally consistent with the original EWAS results. None of the selected CpGs from the tissue-specific EWASs were replicated in our methylation data from whole blood. We were also unable to replicate any of the CpGs associated with HbA1c levels in the healthy control individuals of our sample, while two CpGs (in ABCG1 and CCDC57) for fasting glucose were replicated at a nominal significance level (p < 0.05). CONCLUSIONS/INTERPRETATION: A number of differentially methylated CpGs reported to be associated with type 2 diabetes in the EWAS literature were replicated in blood and show promise for clinical use as disease biomarkers. However, more prospective studies are needed to support the robustness of these findings.
引用
- Walaszczyk E, Luijten M, Spijkerman AMW, et al. DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA1c levels: a systematic review and replication in a case-control sample of the Lifelines study. Diabetologia. 2017. PMID: 29164275. doi:10.1007/s00125-017-4497-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。